[PS2] Presidential Session 2
【E】

[PS2-2] KEYNOTE-355 Asian Subset: Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for Triple-Negative Breast Cancer

^○Toshimi Takano^1,2, Javier Cortes^3,4, David W. Cescon⁵, Seock-Ah Im⁶, Mastura Md Yusof⁷, Hiroji Iwata⁸, Norikazu Masuda⁹, Chiun-Sheng Huang¹⁰, Chi-Feng Chung¹¹, Koichiro Tsugawa¹², Yeon Hee Park¹³, Koji Matsumoto¹⁴, Kenichi Inoue¹⁵, Ava Kwong¹⁶, Sherene Loi¹⁷, Wei Fu¹⁸, Wilbur Pan¹⁸, Valia Karantza¹⁸, Hope S. Rugo¹⁹, Peter Schmid²⁰ (1.The Cancer Institute Hospital of JFCR, Tokyo, Japan, 2.Toranomon Hospital, Tokyo, Japan, 3.International Breast Cancer Center (IBCC), Quiron Group, Madrid and Barcelona, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain, 4.Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain, 5.Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, 6.Seoul National University Hospital, Seoul, Republic of Korea, 7.Cancer Center at Pantai Hospital, Kuala Lumpur, Malaysia, 8.Aichi Cancer Center Hospital, Nagoya, Aichi, Japan, 9.Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan, 10.National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, 11.Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, 12.St Marianna University School of Medicine Hospital, Kawasaki, Japan, 13.Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 14.Hyogo Cancer Center, Akashi, Hyogo, Japan, 15.Saitama Cancer Center, Saitama, Japan, 16.Queen Mary and Tung Wah Hospital and The University of Hong Kong-ShenZhen Hospital, China, 17.Peter MacCallum Cancer Centre and The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Parkville, Melbourne, VIC, Australia, 18.Merck & Co., Inc., Kenilworth, NJ, USA, 19.University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA, 20.Barts Cancer Institute, Centre for Experimental Cancer Medicine, London, UK)